Vertex Pharmaceuticals (VRTX) reachead $484.01 at the closing of the latest trading day, reflecting a +0.11% change compared to its last close.

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research Report) and Apellis ...

Walmart's "everyday low prices" should attract customers even if a recession comes. Which group of individuals is in the best ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price boosted by Royal Bank of Canada from $408.00 to $420.00 in a research report sent to investors on Tuesday morning,Benzinga ...

Wells Fargo analyst Mohit Bansal maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target ...

Vertex Pharmaceuticals Inc. closed 5.23% below its 52-week high of $519.88, which the company achieved on November 8th.

Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.